BRPI0410720A - quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase - Google Patents

quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase

Info

Publication number
BRPI0410720A
BRPI0410720A BRPI0410720-9A BRPI0410720A BRPI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A BR PI0410720 A BRPI0410720 A BR PI0410720A
Authority
BR
Brazil
Prior art keywords
pyrido
pyrimidines
compounds
formula
tyrosine kinase
Prior art date
Application number
BRPI0410720-9A
Other languages
English (en)
Inventor
Samit Kumar Bhattacharya
Jinshan Chen
Richard Damian Connell
John Charles Kath
Goss Stryker Kauffman
Blaise Scott Lippa
Joel Morris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0410720A publication Critical patent/BRPI0410720A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"QUINAZOLINAS E PIRIDO¢3.4-D!PIRIMIDINAS COMO INIBIDORES DO RECEPTOR DE TIROSINA CINASE". A invenção refere-se a compostos de fórmula 1 e a seus sais, pró-fármacos e solvatos farmaceuticamente aceitáveis, em que R¬ 1¬, R¬ 3¬, R¬ 4¬, R¬ 11¬, N, Z, A, m e p são como definido aqui. A invenção também se refere a métodos de tratamento de crescimento celular anormal em mamíferos por administração dos compostos de fórmula (I) e com composições farmacêuticas para tratar tais distúrbios os quais contêm os compostos de fórmula (I). A invenção também refere-se a métodos de preparar os compostos de fórmula (I).
BRPI0410720-9A 2003-05-27 2004-05-17 quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase BRPI0410720A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47381703P 2003-05-27 2003-05-27
PCT/IB2004/001687 WO2004106308A1 (en) 2003-05-27 2004-05-17 Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0410720A true BRPI0410720A (pt) 2006-06-20

Family

ID=33490652

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410720-9A BRPI0410720A (pt) 2003-05-27 2004-05-17 quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase

Country Status (7)

Country Link
US (1) US7585869B2 (pt)
EP (1) EP1636195A1 (pt)
JP (1) JP2007501854A (pt)
BR (1) BRPI0410720A (pt)
CA (1) CA2527017A1 (pt)
MX (1) MXPA05012839A (pt)
WO (1) WO2004106308A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
AU2002246855B2 (en) * 2000-10-23 2005-12-22 Smithkline Beecham Corporation Novel compounds
KR20040103972A (ko) * 2002-04-19 2004-12-09 스미스클라인 비참 코포레이션 신규 화합물
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
JPWO2005095419A1 (ja) * 2004-04-01 2008-02-21 武田薬品工業株式会社 チアゾロピリミジン誘導体
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
AU2006229995A1 (en) * 2005-03-25 2006-10-05 Glaxo Group Limited Process for preparing pyrido(2,3-d)pyrimidin-7-one and 3,4-dihydropyrimido(4,5-d)pyrimidin-2(1H)-one derivatives
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
JP2008535822A (ja) * 2005-03-25 2008-09-04 グラクソ グループ リミテッド 新規化合物
UY29439A1 (es) * 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
WO2007029251A2 (en) * 2005-09-06 2007-03-15 T.K. Signal Ltd. Polyalkylene glycol derivatives of 4- (phenylamino)quinazolines useful as irreversible inhibitors of epidermal gr0wth fact0r receptor tyrosine kinase
US20090131420A1 (en) * 2005-10-07 2009-05-21 Pandey Surendrakumar S Novel Heterocyclic Analogs of Biphenyl Ethers
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
ATE541844T1 (de) * 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
WO2007076035A2 (en) * 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
CA2663436A1 (en) 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
ES2470341T3 (es) * 2007-04-05 2014-06-23 Amgen, Inc Moduladores de la aurora cinasa y método de uso
EP2398797B1 (en) * 2009-02-17 2013-11-06 Boehringer Ingelheim International GmbH Pyrimido[5,4-d]pyrimidine derivatives for the inhibition of tyrosine kinases
CN101619063B (zh) * 2009-06-02 2011-08-10 华中师范大学 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9120749B2 (en) * 2010-07-30 2015-09-01 Oncotherapy Science, Inc. Quinoline derivatives and MELK inhibitors containing the same
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
WO2013152135A1 (en) * 2012-04-04 2013-10-10 Dawei Zhang Substituted quinolines as bruton's tyrosine kinases inhibitors
WO2013173254A1 (en) * 2012-05-14 2013-11-21 Dawei Zhang Bicyclic compounds as kinases inhibitors
CA2787472A1 (en) * 2012-08-22 2014-02-22 Pharmascience Inc. Protein kinase inhibitors
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
SG11201702147TA (en) 2014-09-17 2017-04-27 Celgene Quanticel Res Inc Histone demethylase inhibitors
US10030017B2 (en) 2014-09-17 2018-07-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
WO2017040982A1 (en) 2015-09-02 2017-03-09 The Regents Of The University Of California Her3 ligands and uses thereof
TWI804987B (zh) * 2015-12-24 2023-06-11 日商協和麒麟股份有限公司 α、β不飽和醯胺化合物
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
TW202012391A (zh) * 2018-07-04 2020-04-01 日商第一三共股份有限公司 二芳基醚型喹唑啉衍生物
CA3175102A1 (en) * 2020-03-13 2021-09-16 Suzhou Zanrong Pharma Ltd. Erbb receptor inhibitors as anti-tumor agents
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023195773A1 (ko) * 2022-04-05 2023-10-12 보로노이 주식회사 헤테로아릴 유도체 및 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (pt) * 1994-11-12 1997-12-01 Zeneca Ltd
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
AR007855A1 (es) * 1996-07-13 1999-11-24 Glaxo Group Ltd Compuestos heterociclicos fusionados como inhibidores de proteina tirosina quinasa, sus metodos de preparacion, intermediarios, uso en medicinay composiciones farmaceuticas que los contienen
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
AU2717899A (en) * 1998-01-26 1999-08-09 Smithkline Beecham Plc Quinoline derivatives as antibacterials
GB2345486A (en) * 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
GB9910577D0 (en) * 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
HK1046688A1 (zh) * 1999-09-21 2003-01-24 Astrazeneca Ab 喹唑啉化合物和含有喹唑啉化合物的藥物組合物
CN1437594A (zh) * 2000-06-22 2003-08-20 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
US6603005B2 (en) * 2000-11-15 2003-08-05 Aventis Pharma S.A. Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them
ES2263743T3 (es) * 2001-04-13 2006-12-16 Pfizer Products Inc. Derivados de 4-aminopiridopirimidina sustituidos con un grupo biciclico.
DE10136459A1 (de) * 2001-07-26 2003-02-13 Bosch Gmbh Robert System mit einer Werkzeugaufnahme
RU2004116911A (ru) * 2001-11-03 2005-11-10 Астразенека Аб (Se) Производные хиназолина в качестве противоопухолевых средств
NZ536114A (en) * 2002-03-30 2007-11-30 Boehringer Ingelheim Pharma 4-(N-phenylamino)-quinazolines / quinolines as tyrosine kinase inhibitors
EP1521747B1 (en) * 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7276906B2 (en) * 2002-11-20 2007-10-02 Koninklijke Philips Electronics N.V. Self-shielded gradient field coil for magnetic resonance imaging
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives

Also Published As

Publication number Publication date
US20040242604A1 (en) 2004-12-02
EP1636195A1 (en) 2006-03-22
JP2007501854A (ja) 2007-02-01
US7585869B2 (en) 2009-09-08
WO2004106308A1 (en) 2004-12-09
CA2527017A1 (en) 2004-12-09
MXPA05012839A (es) 2006-05-17

Similar Documents

Publication Publication Date Title
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BRPI0713555A2 (pt) ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
BR0312648A (pt) Processo para preparação de certos compostos pirrolo triazina
BRPI0913580B8 (pt) compostos de pirrolopiridinas como inibidores de quinase e composição farmacêutica compreendendo os referidos compostos
MXPA05000715A (es) Inhibidores novedosos de cinasas.
CZ30697A3 (en) Substituted quinazoline derivatives, process of their preparation and pharmaceutical composition containing thereof
BRPI0313942C1 (pt) derivados de benzimidazol úteis como agentes antiproliferativos, seus processos de preparação, composição farmacêutica compreendendo os mesmos e usos dos referidos compostos nas preparações de composições farmacêuticas
BR0008202A (pt) Derivados de quinolin-2-ona substituìdos com heteroarilas úteis como agentes contra o câncer
BR0111548A (pt) Derivados bicìclicos substituìdos para o tratamento de crescimento de célula anormal
BRPI0418231A (pt) compostos de pirrolotriazina como inibidores da cinase
WO2004001059A3 (en) Heterocyclic inhibitors of kinases
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
BRPI0713923B8 (pt) compostos de ciclopentanos de pirimidila hidroxilados e metoxilados, composição farmacêutica compreendendo os referidos compostos, método de preparação de um composto, e uso dos mesmos
BRPI0514537A (pt) compostos de aminoeteroarila substituìdo com pirazol como inibidores de proteìna quinase
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
MX2012002875A (es) Derivados de 6-amino-quinazolina o 3-ciano-quinolina, metodos de preparacion y usos farmaceuticos de los mismos.
BRPI0520812A2 (pt) método para preparar um composto de quinolina 4-substituìda, e, composto
BRPI0108841B8 (pt) derivado de pirimidina, processo para prepapar o mesmo, e composição farmacêutica
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
BRPI0417478A (pt) 2,6-bis-heteroaril-4-aminopirimidinas como antagonistas de receptor de adenosina
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
NZ594353A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
MX2009006018A (es) Derivados de quinuclidinol como antagonistas de receptores muscarinicos.
AU4483000A (en) Inhibitors of c-jun n-terminal kinases (jnk)
BRPI0417520A (pt) 1h-pirrolo[3,2-b, 3,2-c, e 2,3-c]piridina-2-carboxamidas substituìdas e análogos relatados como inibidores de caseìna cinase i-epsilon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.